Serenoa repens for benign prostatic hyperplasia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Tacklind, James ^a   MacDonald, Roderick ^a   Rutks, Indy ^a   Wilt, Timothy J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

*Phytotherapy; *Serenoa; Androgen antagonists *therapeutic use ; Humans; Male; Plant extracts therapeutic use ; Prostatic hyperplasia *drug therapy ; Randomized controlled trials as topic

Indexed keywords

ALPHA TOCOPHEROL; CARMINIC ACID; CERNITIN; FINASTERIDE; GELATIN; GESTONORONE CAPROATE; GLYCEROL; PHOSPHATIDYLCHOLINE; PLACEBO; PROPOLIS; PROSTAGUTT; PROSTASERENE; PROSTATAPLEX; SABAL EXTRACT; SITOSTEROL; SOYBEAN OIL; TAMSULOSIN; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT; ANTIANDROGEN; PLANT EXTRACT;

ASTHENIA; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; EMBASE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIBIDO; LOWER URINARY TRACT SYMPTOM; MEDLINE; META ANALYSIS; MICTURITION; NOCTURIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHYTOTHERAPY; PROSTATE HYPERTROPHY; REVIEW; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; VANILLA; MALE; RANDOMIZED CONTROLLED TRIAL; SABAL; DRUG EFFICACY; LIBIDO DISORDER; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERENOA; URINATION;

EID: 70349152239     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001423.pub2     Document Type: Review

References (73)

1. Bauer HW. Casarosa C. Cosci M. Fratta M. Blessmann G. Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [German] [Sabalfrucht-Extrakt zur Behandlung der benignen Prostatahyperplasie. Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin 1999;141(25):127-132
2. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes E, Goldberg H, Avins AL. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine 2006;354(6):557-566 (Pubitemid 43209103)
3. Boccafoschi C, Annoscia S. Confronto fra estratto di serenoa repens e placebomediate prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983;50:1257-1268 (Pubitemid 14013091)
4. Braeckman J. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. European Journal of Clinical Research 1997;9:247-259
5. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology 1990;66(6):639-641 [MEDLINE: 1991091633]
6. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauqil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. The Prostate 1996;29(4):231-240 [MEDLINE: 1997030765] (Pubitemid 26365288)
7. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. British Journal of Clinical Pharmacology 1984;18:461-462 [MEDLINE: 1985023088] (Pubitemid 14033836)
8. Cukier J, Ducassou J, Le Guillou M, Leriche A, Lobel B, Toubol J. [Permixon versus placebo; resultats d'une étude multicentrique]. Comptes Rendus de Therapeutique et de Pharmacologie Clinique 1985;4:15-21.
9. * Debruyne F, Koch G, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Groupe d'etude PERMAL. Comparison of a phytotherapeutic agent (permixon) with an a-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study [Comparaison d'un produit de phytotherapie (permixon) et d'un alphabloquant (tamsulosine) dans le traitement de l'hypertrophie benigne de la prostate: etude internationale randomisee d'une durée de 12 mois]. Progrès en Urologie 2002;41:497-507.
10. Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation 1995;5:291-297
11. Emili E, Lo Cigno M, Petrone U. [Risultati clinici su un nuovo farmaco nella terapia dell'ipertofia della prostata (Permixon)]. Urologia 1983;50:1042-1048
12. Engelmann U, Walther C, Bondarenko B, Funk P, Schläfke S. Efficacy and safety of a combination of sabal and urtica extract in lower urniary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittel-Forschung 2006;56(3):222-229
13. Gabric V, Miskic H. [Behandlung des benignen prostata - adenoms und der chronischen prostatatitis]. Therapiewoche 1987;37:1775-1788
14. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58(6):960-964 (Pubitemid 34017279)
15. Glémain P, Coulange C, Billebaud T, Gattegno B, Muszynski R, Loeb G, and the OCOS workgroup. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie 2002;12:395-403.
16. Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, Tamsulosin, and Serenoa repens plus Tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology 2007;39:879-886 (Pubitemid 47365400)
17. Lopatkin N, Sivkov A, Walther C, Schläfke S, Medvedev A, Avdeichuk J, Golubev G, Melnik K, Elenberger N, Engelmann U. Longterm efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms - a placebo-controlled, double-blind, multicenter trial [Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial]. World Journal of Urology 2005;23:139-146
18. Löbelenz J. [Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). klinische prufung im stadium I und II]. Therapeutikon 1992;6(1-2):34-37
19. Mandressi S, Tarallo U, Maggioni A, Tombolini P, Rocco F, Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon) compared to that of the extract of Pygeum africanum and a placebo. Urologia 1983;50(4):752-758
20. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA, deKernion JB. Effects of a saw palmetto herbal blend inmen with symptomatic benign prostatic hyperplasia. The Journal of Urology 2000;163(5):1451-1456 (Pubitemid 30226294)
21. Mattei FM, Capone M, Acconcia A. Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme. TW Urologie Nephrologie 1990;2:346-350 (Pubitemid 20384138)
22. Metzker H, Kieser M, Holscher U. Wirksamkeit eines Sabal- Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH). Der Urologe B 1996;36(4):292-300. (Pubitemid 26285190)
23. Pannunzio E, D'Ascenzo R, Giardinetti F, Civili P, Persichelli E. Serenoa repens vs. gestonorone caproato nel trattamento dell'ipertofia prostatica benigna: Studio randomizzato. Urologia 1986;53(5):696-705.
24. Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology 2001;33:217-225 (Pubitemid 34575369)
25. Reece Smith H, Memon A, Smart CJ, Dewbury K. The value of permixon in benign prostatic hypertrophy. British Journal of Urology 1986;58:36-40. (Pubitemid 16133775)
26. Roveda S, Colombo P. [Sperimentazione clinica controllata sulla bioequivalenza terapeutica e sulla tollerabilita dei prodotti a base di Serenoa repens in capsule da 160 mg o capsule rettali da 640 mg]. Archivio di Medicina Interna 1994;46(2):61-75.
27. Shi R, Xie Q, Gang X, Lun J, Life C, Pantuck A, Rao J. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in shanghai, china. The Journal of Urology 2008;179:610-615
28. Sökeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU International 2000;86:439-442
29. * Sökeland J, Albrecht J. Combined sabal and urtica extract compared with finasteride inmen with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome [Kombination aus Sabal- und Urticaestrakt vs. finasterid bei BPH (Stad. I bis II nach Alken); Vergleich der therapeutischen wirksamkeit in einer einjahrigen doppelblindstudie]. Urologe A 1997;36(4):327-333 [MEDLINE: 1997419443]
30. Tasca A, Barulli M, Cavazzana A, Zattoni F, Artibani W, Pagano F. [Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo]. Minerva Urologica e Nefrologica 1985;37:87-91. [MEDLINE: 1986019370]
31. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International 2003;92:267-270 (Pubitemid 36966591)
32. Adriazola Semino M, Lozano Ortega JL, Garcia Cobo E, Tejeda Banez E, Romero Rodriguez F. Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens [Tratamiento sintomatico de la hipertrofia benigna de prostata. Estudio comparativo entre prazosin y Serenoa repens]. Archivos Espanoles de Urologia 1992;45(3):211-213 [MEDLINE: 1993037631]
33. Comar OB, Di Rienzo A. Mepartricin versus Serenoa repens: double-blind study in 20 cases of benign prostate hypertrophy. Rivista Italiana di Biologia e Medicina 1986;6(2):122-125 (Pubitemid 18037623)
34. Di Siverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera M, Sciarra F. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. European Urology 1992;21(4):309-314 [MEDLINE: 1993093014]
35. Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA. Saw palmetto (Serenoa repens) inmen with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998;51(6):1003-1007
36. Grasso M, Montesano A, Buonaguidi A, Castelli M, Lania C, Rigatti P, Rocco F, Cesana BM, Borghi C. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Archivos Españoles de Urología 1995;48(1):97-103. [MEDLINE: 1995251418]
37. Pecoraro S, Annecchiarico A, Gambardella M-C, Sepe G. Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate [Effetto del pretrattamento con serenoa repens sul sanguinamento associato a resezione transuretrale della prostata]. Minerva Urologica e Nefrologica 2004;56:73-78
38. Popa G, Hägele-Kaddour H, Walther C. [Symptomatische wirksamkeit eines sabal-urtica-kombinationspräparats in der therapie des benignen prostatasyndroms: ergebnisse einer plazebokontrollierten doppelblindstudie]. MMW Fortschritte der Medizin 2005;147(Supp 3):103-108
39. Sivkov A, Köhler S, Engelmann U, Medvedev A, Lopatkin N. Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS - a placebo-controlled, double-blind, multicenter trial. Urologe A 2001;40 (Suppl 1):S19.
40. Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq W, Malice MP. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. European Urology 1994;26(3):247-252 [MEDLINE: 1995104266] (Pubitemid 24309673)
41. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A. BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. European Urology 2003;44:549-555 (Pubitemid 37328630)
42. * Vela-Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. European Urology 2003;44:549-555
43. Vela-Navarrete R, Escribano-Burgos M, Lopez Farre A, Garcia-Cardoso J, Manzarbeitia F, Carrasco C. Serenoa repens treatment modifies BAX/BCL-2 index expression and CASPASE-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. The Journal of Urology 2005;173:507-510
44. Weissser H, Behnke, Helpap B, Bach D, Krieg M. Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. European Urology 1997;31(1):97-101. [MEDLINE: 1997184773] (Pubitemid 27058112)
45. Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. British Journal of Urology 1979;51(2):129-134
46. Avins AL, Bent S, Staccone S, Badua E, Padula A, Goldberg H, Neuhaus J, Hudes E, Shinohara K, Kane C. A detailed safety assessment of a saw palmetto extract. Complementary Therapies in Medicine 2008;16:147-154
47. Bales G, Christiano AP, Kirsh E, Gerber GS. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 1999;54:86-89 (Pubitemid 29323338)
48. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics of the National Center for Health Statistics 2004;27(343):1-19.
49. Berry SL, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. The Journal of Urology 1984;132:474-479 [MEDLINE: 1984292487]
50. Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU International 2004;93(6):751-756 (Pubitemid 38497023)
51. Buck AC. Phytotherapy for the prostate. British Journal of Urology 1996;78(3):325-326 [MEDLINE: 1997036289]
52. Buck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. The Journal of Urology 2004;172:1792.
53. Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and the indications for therapeutic intervention. Urology Clinics of North America 1990;17:509-516 [MEDLINE: 1990327595]
54. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008.. www.cochranehandbook. org (accessed September 2008). [: http://www.mrc-bsu.cam. ac.uk/cochrane/handbook/]
55. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology 2008;179:2119-2125
56. Di Silverio F, Flammia GP, Sciarra A, Caponera M, Mauro M, Buscarini M, Tavani M, D'Eramo G. Plant extracts in benign prostatic hyperplasia. Minerva Urologica e Nefrologica 1993;45:143-149 [MEDLINE: 1994294881]
57. Dickersin K, Scherer R, Lefebvre C. Indentifying relevant studies for systematic reviews. British Medical Journal 1994;312:944-947 [MEDLINE: 1995195448]
58. Dreikorn K, Richter R, Schönhöfer PS. Conservative nonhormonal treatment of patients with benign prostatic hyperplasia. Urologe A 1990;29(1):8-16. [PUBMED: 1690486] (Pubitemid 20105517)
59. Follmann D, Elliott P, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45(7):763-773
60. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data?. Neuropsychopharmacology 1992;6:39-63. [MEDLINE: 1992238968]
61. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin and finasteride, or both in benign prostatic hyperplasia. New England Journal of Medicine 1996;335:533-539 (Pubitemid 26272307)
62. Wei JT, Calhoun EA, Jacobsen SJ. Benign prostatic hyperplasia. In: Litwin MS, Saigal CS, editors. Urologic Diseases in America. Washington, DC: US Government Publishing Office, 2007.
63. Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. Journal of the American Medical Association 1995;273:607-609 [MEDLINE: 1995147312]
64. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clinical practice guideline. Quick reference guide for clinicians 1994;8:1-17. [PUBMED: 7507389]
65. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine 2003;349:2387-2398
66. McGuire E. Detrusor response to obstruction. NIH Publication No. 87-2881 1987; Vol.221.
67. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. Journal of Clinical Epidemiology 2001;54:935-944 (Pubitemid 32771319)
68. Platz EA, Smit E, Curhan GC, Nyberg Jr LM, Giovannucci E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 2002;59:877-883 (Pubitemid 34522180)
69. Schulz KF, Chalmers I, Hayes RJ Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-412 [MEDLINE: 1995123716]
70. Vacherot F, Azzouz M, Gil-Diez-de-Medina S, Colombel M, de la Taille A, Lefrere Belda MA, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. The Prostate 2000;45:507. (Pubitemid 30823403)
71. Weisser H, Tunn S, Behnke B, Krieg M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. The Prostate 1996;28:300. (Pubitemid 26138135)
72. Wilt TJ, Ishani A, Stark G, Mac Donald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. Journal of the American Medical Association 1998;280(18):1604-1609 (Pubitemid 28520650)
73. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD001423]